Novartis's drug reduces heart failure deaths: study

ZURICH Mon Sep 24, 2012 1:30am EDT

Related Topics

ZURICH (Reuters) - Novartis's investigational medicine RLX030 reduced the number of deaths in patients with acute heart failure, the drugmaker said on Monday based on the results of a late-stage trial.

RLX030 is form of the human hormone relaxin-2. Serelaxin acts by relaxing the blood vessels, leading to reduced stress on the heart and kidneys, the firm said in a statement.

(Reporting by Catherine Bosley)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.